Related Experiment Video
Updated: Aug 21, 2026
Quantification of Breast Cancer Cell Invasiveness Using a Three-dimensional (3D) Model
Published on: June 11, 2014
Differentiation-inducing quinolines as experimental breast cancer agents in the MCF-7 human breast cancer cell model
Anna R Martirosyan1, Rayhana Rahim-Bata, Andrew B Freeman
1Department of Biochemistry & Molecular Pharmacology, West Virginia University, Morgantown, WV 26506, USA.
Abstract:
The purpose of this work is to develop agents for cancer differentiation therapy. We showed that five antiproliferative quinoline compounds in the National Cancer Institute database stimulated cell differentiation at growth inhibitory concentrations (3-14 microM) in MCF-7 human breast tumor cells in vitro. The differentiation-inducing quinolines caused lipid droplet accumulation, a phenotypic marker of differentiation, loss of Ki67 antigen expression, a cell cycle marker indicative of exit into G0, and reduced protein levels of the G1--S transcription factor, E2F1. The antimalarial quinolines, chloroquine, hydroxychloroquine and quinidine had similar effects in MCF-7 cells, but were 3-10 times less potent than the NSC compounds. NSC3852 and NSC86371 inhibited histone deacetylase (HDAC) activity in vitro and caused DNA damage and apoptosis in MCF-7 cells, consistent with their differentiation and antiproliferative activities. However, the HDAC assay results showed that for other compounds, direct HDAC enzyme inhibition was not required for differentiation activity. E2F1 protein was suppressed by all differentiation quinolines, but not by non-differentiating analogs, quinoline and primaquine. At equivalent antiproliferative concentrations, NSC69603 caused the greatest decrease in E2F1 protein (90%) followed by antimalarials quinidine and hydroxychloroquine. NSC69603 did not cause DNA damage. The other NSC compounds caused DNA damage and apoptosis and reduced E2F1 levels. The physicochemical properties of NSC3852, NSC69603, NSC86371, and NSC305819 predicted they are drug candidates suitable for development as experimental breast tumor cell differentiation agents. We conclude DNA damage and reductions in E2F1 protein are mechanistically important to the differentiation and antiproliferative activities of these quinoline drug candidates.
Insights
This study identifies quinoline compounds that promote cancer cell differentiation, offering potential for new breast tumor therapies. These agents reduce E2F1 protein levels and induce differentiation markers in MCF-7 cells.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Cancer differentiation therapy aims to induce tumor cell maturation, halting proliferation.
- Quinolines are a class of compounds with diverse biological activities, including antiproliferative effects.
- Identifying novel agents that can stimulate cancer cell differentiation is a key goal in oncology drug development.
Purpose of the Study:
- To develop novel quinoline-based agents for cancer differentiation therapy.
- To investigate the differentiation-inducing potential of specific quinoline compounds in human breast tumor cells.
- To elucidate the molecular mechanisms underlying the differentiation and antiproliferative activities of these quinoline candidates.
Main Methods:
- Screening of National Cancer Institute database quinoline compounds for differentiation activity in MCF-7 cells.
- Assessment of phenotypic markers of differentiation, including lipid droplet accumulation and Ki67 antigen expression.
- Analysis of protein levels of the transcription factor E2F1 and histone deacetylase (HDAC) activity.
- Evaluation of DNA damage and apoptosis induction in treated cells.
Main Results:
- Five antiproliferative quinoline compounds stimulated MCF-7 cell differentiation at growth-inhibitory concentrations.
- Differentiation was associated with lipid droplet accumulation, decreased Ki67 expression, and reduced E2F1 protein levels.
- Antimalarial quinolines (chloroquine, hydroxychloroquine, quinidine) showed similar but less potent effects.
- NSC3852 and NSC86371 inhibited HDAC activity, induced DNA damage, and apoptosis; however, HDAC inhibition was not universally required for differentiation.
- E2F1 suppression was observed for all differentiating quinolines, with NSC69603 showing the most significant reduction without causing DNA damage.
Conclusions:
- Quinolines can induce differentiation and antiproliferative effects in breast cancer cells.
- Reduction in E2F1 protein levels is a key mechanism for quinoline-induced differentiation.
- Specific quinoline compounds (NSC3852, NSC69603, NSC86371, NSC305819) show promise as drug candidates for experimental breast tumor differentiation therapy.
More Related Videos
11:13Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
Published on: June 9, 2023
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012